BioSpace News Archive

UCB, a global biopharmaceutical company, today announced positive top-line results from two Phase 3 studies, BE HEARD I and BE HEARD II, evaluating the efficacy and safety of bimekizumab in adults with moderate to severe hidradenitis suppurativa.

Regulatory News: Aptorum Group Limited today announced a private offering of USD$3 million aggregate principal amount of convertible note due 2023 (the “Note”) to be used as part of the Company’s daily operations and clinical program.

BeiGene, a global biotechnology company, is convening diverse stakeholders to amplify the mental health needs of the cancer community during an event hosted for patient advocates and scientists attending the American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans.

Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, announced the pricing of an underwritten offering of 15,384,616 shares of its common stock at a price of $6.50 per share.

Zymeworks Inc. (NYSE: ZYME) today presented new clinical data for zanidatamab, the company’s investigational HER2-targeted bispecific antibody, in combination with palbociclib, a CDK4/6 inhibitor, and fulvestrant, a selective estrogen receptor degrader, in patients with heavily pretreated HER2-positive hormone-receptor positive metastatic breast cancer.

Azura Ophthalmics Ltd. today announced that positive 3-month efficacy and safety results from its Phase 2b study of AZR-MD-001 0.5% in Meibomian Gland Dysfunction (MGD), were presented for the first time at Ophthalmology Innovation Summit XII (OIS) on Saturday, December 3, 2022 in San Diego, California.

Positive Physicians Insurance Company (“Positive”), a leading medical professional liability (MPL) insurer serving healthcare providers across 10 states, today announced it has partnered with Coalition, the world’s first Active Insurance provider designed to prevent digital risk before it strikes, to provide Positive’s insured physicians and healthcare providers with competitively priced and broader coverage options.

Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®) (STO:SOBI), announced today that Health Canada has approved Empaveli™ (pegcetacoplan), a complement inhibitor, for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have an inadequate response to, or are intolerant of, a C5 inhibitor.

Nordic Nanovector ASA (OSE: NANOV) (“Nordic Nanovector” or the “Company”) today announces an update following the Extraordinary General Meeting held on 1 December at which the proposed merger transaction with APIM Therapeutics AS (“APIM”) did not obtain a sufficient majority of votes and was therefore voted down.

Drug discovery and development have evolved drastically in the recent past and continue to trend with emerging advancements. Innovative and sophisticated approaches are being incorporated with novel modalities emerging continuously through multifaceted approaches.